Corcept Therapeutics (CORT) Stock Forecast & Price Target

Corcept Therapeutics Inc. is anticipated to experience significant annual sales growth for its product, Korlym, projected at 19% to 26% year-over-year, with FY2025 guidance estimating sales between $800 million and $850 million, indicating a robust demand despite recent commercial challenges. The company’s commitment to expanding its treatment offerings, particularly with relacorilant showing promising results in clinical trials for various cancers, positions it well for future growth in a lucrative market. Overall, the combination of increasing sales, ongoing market expansion for its Cushing's syndrome franchise, and the potential to broaden its treatment scope suggests a strong foundation for sustained financial performance.

Corcept Therapeutics faces a negative outlook due to expected near-term earnings headwinds, including a potential downward revision of 2025 revenue guidance ahead of its upcoming financial report. The company's projected sales for Korlym have been lowered by approximately 10% for the latter half of 2025, resulting in a revised total estimate of $824 million, which falls short of the previously communicated guidance range of $850 million to $900 million. Additionally, management's strategy delay in activating two pharmacies by year-end to address supply chain issues further exacerbates concerns regarding the company's ability to meet sales expectations.